Complex PCI: Nothing Is Simple in Shock Patients!-To Support or Not to Support: MCS in AMI-Shock, Dr. Benham N. Tehrani

To Support or Not to Support: MCS in AMI-Shock, Dr. Benham N. Tehrani

Video Transcription

Video Summary

Despite advances in acute myocardial infarction (AMI) management, outcomes in cardiogenic shock remain poor. Mechanical circulatory support (MCS) shows potential but mixed results due to heterogeneous patient populations and trial limitations. Recent studies like the DANGER Shock trial highlight benefits of the Impella microaxial pump in select patients, demonstrating improved survival and reduced adverse cardiac events, leading to a class 2A guideline recommendation. Optimal care requires understanding shock complexity, patient selection, device choice, and multidisciplinary protocols. Regionalized networks and longitudinal management are crucial for improving outcomes, emphasizing standardized approaches tailored to individual hemodynamics and clinical profiles for effective MCS use.

Keywords

acute myocardial infarction

cardiogenic shock

mechanical circulatory support

Impella microaxial pump

DANGER Shock trial